Agiomix BRCA panel uses the Next Generation Sequencing method to find out the mutations in the associated genes. The test results enable clinicians to identify a mutation in BRCA panel genes indicating a potential risk of development of Breast cancer.
Under OncoSeq® Breast, screening is done for the below 15 genes to identify the cause of the disease:
ATM, BARD1, BRCA1, BRCA2, BRIP1, CDH1, CHEK2, MUTYH, NBN, PALB2, PTEN, RAD50, RAD51C, RAD51D, TP53.
Under OncoSeq® Colon, screening is done for the below 10 genes to identify the cause of the disease:
APC, EPCAM, MLH1, MSH2, MSH6, MUTYH, PMS2, PTEN, STK11, TP53
Under OncoSeq® Repair, screening is done for the below 14 genes to identify the cause of the disease:
ATM, BARD1, BRCA1, BRCA2, BRIP1, CHEK2, NBN, PALB2, RAD51C, RAD51D, MLH1, MSH2, MSH6, PMS2 (Does not include MRE11A)
Under OncoSeq® Guard, screening is done for the below 2 genes to identify the cause of the disease:
Who should get OncoSeq® Breast Screening done?
- An individual who is diagnosed with the cancer
- When there is a family history of cancer
- When there is an increased risk of cancer
- When you are worried about the risk of cancer
- DNA in TE Buffer or Water
- Peripheral Blood in EDTA Tubes
Relevant Syndromes Covered:
Hereditary Breast and Ovarian Cancer Syndrome, Li-Fraumeni Syndrome, Cowden (PTEN) Hamartomas Syndrome, Peutz-Jeghers Syndrome, Hereditary Diffuse Gastric Cancer Syndrome
For more details about each panel and a complete list of syndromes, please contact us at 800 – GENOMICS (43666427)